Close Menu

NEW YORK – Adaptive Biotechnologies said Monday after the close of the market that its second quarter revenues decreased 5 percent year over year, primarily due to a COVID-19 pandemic-related drop in its sequencing business.

For the three months ended June 30, 2020, the Seattle-based immune sequencing firm tallied revenues of $21.0 million compared to $22.1 million a year ago, ahead of analysts' average estimate of $18.8 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
22
Sponsored by
Qiagen

Please join GenomeWeb and Qiagen for an online roundtable discussion where a panel of experts will review challenges and opportunities around genomic variant interpretation workflows in the field of oncology.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.